Clinical Pharmacist Intervention to Reduce Drug-related Readmissions Among Older People

NCT ID: NCT03671629

Last Updated: 2024-12-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

700 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-09-19

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomized controlled trial primarily investigates if a clinical pharmacist intervention can reduce drug-related readmissions among patients \>75 years. The intervention targets the transfer between hospital and primary care. In brief, the intervention includes medical chart reviews and patient interviews during a period of 180 days.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

At discharge from the hospital, patients that meet the inclusion criteria are offered to participate in the study. At this point the investigators will also gather baseline data through questionnaires on self-reported adherence (MARS-5) and quality of life (EQ-5D). The participants are randomized to the different study arms according to a stratified procedure based on their cognitive function.

The intervention group will have their charts reviewed every second week and be contacted by the clinical pharmacist through phone within 7 and after 30 and 60 days respectively to discuss their medications. If possible drug-related problems are suspected during the interviews that cannot be solved immediately, the physician is contacted.

Both groups have a follow-up time of 30 and 180 days. After 30 and 180 days, the patients will once again report adherence and quality of life. All other data can be gathered from the medical charts.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Drug Use

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Clinical pharmacist Elderly Adherence Drug-related readmission

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Outcome Assessors
A group of physicians and clinical pharmacists will asses whether readmissions are drug-related or not. This group is blinded.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention group

In addition to a standard medication review at the hospital, this group also receives an enhanced clinical pharmacist service during 180 days after discharge from the hospital.

Group Type EXPERIMENTAL

Enhanced clinical pharmacist service

Intervention Type OTHER

The intervention includes regular medical chart reviews, multiple patient interviews and, if needed, collaboration with the primary care physician.

Control group

This group receives standard care, which might include a medication review at the hospital.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Enhanced clinical pharmacist service

The intervention includes regular medical chart reviews, multiple patient interviews and, if needed, collaboration with the primary care physician.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Living at home
* Acutely admitted
* Registered at one of ten pre-specified primary care health centers

Exclusion Criteria

* Patients unable to communicate or who do not speak Swedish
* Patients scheduled for palliative care
* Patients admitted due to intoxication by alcohol or drug (non prescription)
Minimum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Umeå University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Maria Gustafsson

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Maria Gustafsson, Ph.D

Role: PRINCIPAL_INVESTIGATOR

Umeå University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Medical Centre, University Hospital of Umeå

Umeå, , Sweden

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Sweden

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Kindstedt

Role: CONTACT

Phone: +46706572422

Email: [email protected]

Maria Gustafsson, Ph.D

Role: CONTACT

Phone: +46907853562

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Matsson

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Kindstedt J, Svahn S, Sjolander M, Glader EL, Lovheim H, Gustafsson M. Investigating the effect of clinical pharmacist intervention in transitions of care on drug-related hospital readmissions among the elderly: study protocol for a randomised controlled trial. BMJ Open. 2020 Apr 27;10(4):e036650. doi: 10.1136/bmjopen-2019-036650.

Reference Type DERIVED
PMID: 32345700 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UmU-2018-700

Identifier Type: -

Identifier Source: org_study_id